PET in Breast Cancer Receiving Neoadjuvant Chemotherapy
NCT01396655
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
78
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)
Sponsor
Seoul National University Hospital